Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412531 | 0.87 | MEN1 (0.39) | MEN1KMT2AGCKGRM5RORC | |
| SCHEMBL3763828 | 0.86 | MEN1 (0.39) | MEN1KMT2AGCKGRM5RORC | |
| SCHEMBL15273799 | 0.86 | MEN1 (0.39) | MEN1KMT2AGCKGRM5RORC | |
| SCHEMBL1412418 | 0.84 | MEN1 (0.38) | MEN1KMT2AGCKGRM5CREBBP | |
| SCHEMBL534143 | 0.84 | MEN1 (0.38) | MEN1KMT2AGCKGRM5RORC | |
| SCHEMBL3149260 | 0.84 | MEN1 (0.38) | MEN1KMT2AGCKGRM5RORC | |
| SCHEMBL10576592 | 0.84 | MEN1 (0.38) | MEN1KMT2AGCKGRM5KDM4C | |
| SCHEMBL7188169 | 0.83 | MEN1 (0.37) | MEN1KMT2AGCKGRM5 | |
| SCHEMBL15418523 | 0.83 | MEN1 (0.51) | MEN1KMT2AGCKKDM4C | |
| SCHEMBL1513547 | 0.82 | MEN1 (0.36) | MEN1KMT2AGCKGRM5CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066386-A1 | INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023086341-A1 | INHIBITORS OF KRAS | BIOMEA FUSION, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066386-A1 | INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MEN1 937/4885KMT2A 2622/4885GCK 2879/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | MEN1 1307/4885KMT2A 2427/4885GCK 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.